Single Center Cetuximab Experience in Head and Neck Cancers

Öz

Head and neck squamous cell carcinomas (HNSCC) are cancers originating from epithelial cells of the oral cavity, pharynx and larynx. It is known to be the seventh most common cancer worldwide. Approximately 5% of patients are diagnosed in the metastatic stage. Within the first 2 years; approximately 50-60% of patients who complete primary treatment returning with relapse. In our study, we aimed to evaluate the efficacy of Cetuximab, an anti-epidermal growth factor (EGFR) monoclonal antibody which used for recurrent unresectable or metastatic HNSCC. The study included 38 patients. 33 (86,8%) of them were male and 5 (13,2%) were female. Median age was 55,5 years. Mean follow-up period was 14,95±18,17 months. The median progression-free survival (PFS) of the patients was 4,6 months and the median overall survival (OS) was 7,1 months. We found shorter survival compared to current literature. However, the rate of metastatic patients and the patients who had previously received chemotherapy were higher in our study.

Anahtar Kelimeler

• cancer
• metastasis
• cetuximab

Baş-Boyun Kanserlerinde Tek Merkez Setüksimab Deneyimi

Öz

Baş boyun squamöz hücreli kanserleri (BBSHK); oral kavite, farinks ve larinks yerleşimli epitelyal hücrelerden kaynaklanan kanserlerdir. Dünya genelinde yedinci en sık görülen kanser olduğu bilinmektedir. Hastaların yaklaşık %5’i metastatik evrede tanı almaktadır. Primer tedavisini tamamlayan hastaların ise yaklaşık %50-60’ı ilk 2 yıl içinde nüks etmektedir. Çalışmamızda nüks lokal tedavilere uygun olmayan ya da metastatik BBSHK hastalarının tedavisinde bir anti-epidermal büyüme faktörü (EGFR) monoklonal antikoru olan setüksimab tedavisinin etkinliğini değerlendirmeyi amaçladık. Çalışmaya 38 hasta dahil edildi. Bunların 33 (%86,8)’ ü erkek; 5 (%13,2)’i kadındı. Median yaş 55,5 idi. Ortalama takip süresi 14,95±18,17 aydı. Hastaların median progresyonsuz sağ kalım (PFS) süresi 4,6 ay ve median genel sağ kalım (OS) süresi ise 7,1 ay idi. Güncel literatür çalışmalarına kıyasla daha kısa sağ kalım süreleri saptadık. Ancak çalışmamızda metastatik hasta oranı ve daha önce kemoterapi almış olan hasta oranı yüksekti.

Anahtar Kelimeler

• cetuximab
• cancer
• neoplasm metastasis

Kaynakça

1. 1. Johnson DE, Burtness B, Leemans CR, et al: Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6:92, 2020
2. 2. Ferlay J, Ervik M, Lam F, et al (eds): Cancer Today (powered by GLOBOCAN 2018). Lyon, France, 2018
3. 3. Sacco, A., Cohen, E., 2015. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 33 (29), 3305–3313.
4. 4. Brockstein, B., Vokes, E., 2020. Treatment of Metastatic and Recurrent Head and Neck Cancer. In: UpToDate [database on the internet]. [cited Feburary 2020]. Available from:. UpToDate, Altham (MA). https://www.uptodate.com/contents/treatment-ofmetastatic-and-recurrent-head-and-neck-cancer#H1.
5. 5. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-6.
6. 6. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibodydependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007;98:1275-80.
7. 7. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53:4637-42.
8. 8. Rivera, F., García-Castaño, A., Vega, N., Vega-Villegas, M. E., & Gutiérrez-Sanz, L. (2009). Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert review of anticancer therapy, 9(10), 1421-1428.

9. 9. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212):1915-1928.
10. 10. Gatta, G., Capocaccia, R., Botta, L., Mallone, S., De Angelis, R., Ardanaz, E., ... & Benhamou, E. (2017). Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. The Lancet Oncology, 18(8), 1022-1039.
11. 11. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101:2222.
12. 12. Fortin, A., Wang, C. S., & Vigneault, É. (2009). Influence of smoking and alcohol drinking behaviors on treatment outcomes of patients with squamous cell carcinomas of the head and neck. International Journal of Radiation Oncology* Biology* Physics, 74(4), 1062-1069.
13. 13.Eichler, M., Keszte, J., Meyer, A., Danker, H., Guntinas–Lichius, O., Oeken, J., ... & Singer, S. (2016). Tobacco and alcohol consumption after total laryngectomy and survival: A German multicenter prospective cohort study. Head & neck, 38(9), 1324-1329.